B

Bergenbio ASA
OSE:BGBIO

Watchlist Manager
Bergenbio ASA
OSE:BGBIO
Watchlist
Price: 8.767 NOK -5.16% Market Closed
Market Cap: 342.7m NOK
Have any thoughts about
Bergenbio ASA?
Write Note

Relative Value

The Relative Value of one BGBIO stock under the Base Case scenario is 0.203 NOK. Compared to the current market price of 8.767 NOK, Bergenbio ASA is Overvalued by 98%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BGBIO Relative Value
Base Case
0.203 NOK
Overvaluation 98%
Relative Value
Price
B
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
93
vs Industry
5
Median 3Y
120 584.9
Median 5Y
1 047 336.9
Industry
7.5
Forward
3 327
vs History
vs Industry
Median 3Y
-207.6
Median 5Y
-2 873.5
Industry
21.3
Forward
-1.5
vs History
vs Industry
Median 3Y
-167.2
Median 5Y
-2 976.3
Industry
21.6
vs History
vs Industry
Median 3Y
-167.2
Median 5Y
-2 970.3
Industry
23.3
vs History
95
vs Industry
16
Median 3Y
321
Median 5Y
2 817.3
Industry
2.5
vs History
96
vs Industry
4
Median 3Y
120 149.9
Median 5Y
1 046 960.3
Industry
7.4
Forward
1 629.4
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
8.8
vs History
vs Industry
Median 3Y
-208.2
Median 5Y
-2 873.7
Industry
4.2
Forward
-0.9
vs History
vs Industry
Median 3Y
-208
Median 5Y
-2 861.8
Industry
4
Forward
-1
vs History
vs Industry
Median 3Y
-166.6
Median 5Y
-2 975.3
Industry
6.1
vs History
vs Industry
Median 3Y
-166.6
Median 5Y
-2 975.3
Industry
3.9
vs History
15
vs Industry
3
Median 3Y
-1 025.3
Median 5Y
-60 525.1
Industry
4.6

Multiples Across Competitors

BGBIO Competitors Multiples
Bergenbio ASA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
NO
Bergenbio ASA
OSE:BGBIO
342.7m NOK 657.7 -2.3 -1 -1
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 472 112 -182 852.2 -222 040.8 -219 507.1
US
Abbvie Inc
NYSE:ABBV
315.4B USD 5.7 62.1 15.4 23.8
US
Amgen Inc
NASDAQ:AMGN
142B USD 4.4 33.6 16.1 30.5
US
Gilead Sciences Inc
NASDAQ:GILD
111.1B USD 3.9 881.5 9.8 9.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
106.2B USD 10 -221.4 21.9 23
US
Epizyme Inc
F:EPE
94.1B EUR 1 831.2 -467.3 -508.9 -495.3
AU
CSL Ltd
ASX:CSL
139.2B AUD 5.8 32.7 20.2 25.2
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
80.8B USD 5.8 17.4 15.8 17.6
US
Seagen Inc
F:SGT
39.3B EUR 17.6 -54.1 -58.1 -52.4
NL
argenx SE
XBRU:ARGX
38.4B EUR 18.1 -350.4 -166.8 -108.6
P/S Multiple
Revenue Growth P/S to Growth
NO
B
Bergenbio ASA
OSE:BGBIO
Average P/S: 3 497 697.5
657.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
38 472 112
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.7
6%
0.9
US
Amgen Inc
NASDAQ:AMGN
4.4
8%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
3.9
3%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10
10%
1
US
E
Epizyme Inc
F:EPE
1 831.2
N/A N/A
AU
CSL Ltd
ASX:CSL
5.8
7%
0.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.8
7%
0.8
US
S
Seagen Inc
F:SGT
17.6
30%
0.6
NL
argenx SE
XBRU:ARGX
18.1
47%
0.4
P/E Multiple
Earnings Growth PEG
NO
B
Bergenbio ASA
OSE:BGBIO
Average P/E: 205.4
Negative Multiple: -2.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -182 852.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
62.1
72%
0.9
US
Amgen Inc
NASDAQ:AMGN
33.6
20%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
881.5
21%
42
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -221.4
14%
N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -467.3 N/A N/A
AU
CSL Ltd
ASX:CSL
32.7
18%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.4
13%
1.3
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.1 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -350.4 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
NO
B
Bergenbio ASA
OSE:BGBIO
Average EV/EBITDA: 16.5
Negative Multiple: -1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -222 040.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.4
9%
1.7
US
Amgen Inc
NASDAQ:AMGN
16.1
18%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
9.8
5%
2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.9
13%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -508.9 N/A N/A
AU
CSL Ltd
ASX:CSL
20.2
12%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.8
11%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.1 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -166.8 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
NO
B
Bergenbio ASA
OSE:BGBIO
Average EV/EBIT: 21.6
Negative Multiple: -1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 507.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.8
24%
1
US
Amgen Inc
NASDAQ:AMGN
30.5
24%
1.3
US
Gilead Sciences Inc
NASDAQ:GILD
9.8
10%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23
13%
1.8
US
E
Epizyme Inc
F:EPE
Negative Multiple: -495.3 N/A N/A
AU
CSL Ltd
ASX:CSL
25.2
16%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.6
12%
1.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -52.4 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -108.6 N/A N/A